- Home
- STTK vs HXHX Comparison
STTK vs HXHX Comparison
Compare STTK & HXHX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- STTK
- HXHX
- Stock Information
- Founded
- STTK 2016
- HXHX 2003
- Country
- STTK United States
- HXHX China
- Employees
- STTK N/A
- HXHX N/A
- Industry
- STTK Biotechnology: Pharmaceutical Preparations
- HXHX Trucking Freight/Courier Services
- Sector
- STTK Health Care
- HXHX Industrials
- Exchange
- STTK Nasdaq
- HXHX Nasdaq
- Market Cap
- STTK 37.6M
- HXHX 36.9M
- IPO Year
- STTK 2020
- HXHX 2025
- Fundamental
- Price
- STTK $1.00
- HXHX $1.57
- Analyst Decision
- STTK Hold
- HXHX
- Analyst Count
- STTK 4
- HXHX 0
- Target Price
- STTK $3.00
- HXHX N/A
- AVG Volume (30 Days)
- STTK 112.0K
- HXHX 141.2K
- Earning Date
- STTK 07-31-2025
- HXHX 01-01-0001
- Dividend Yield
- STTK N/A
- HXHX N/A
- EPS Growth
- STTK N/A
- HXHX N/A
- EPS
- STTK N/A
- HXHX 0.26
- Revenue
- STTK $4,606,000.00
- HXHX $25,571,810.00
- Revenue This Year
- STTK N/A
- HXHX N/A
- Revenue Next Year
- STTK N/A
- HXHX N/A
- P/E Ratio
- STTK N/A
- HXHX $6.09
- Revenue Growth
- STTK 69.65
- HXHX N/A
- 52 Week Low
- STTK $0.69
- HXHX $1.29
- 52 Week High
- STTK $4.99
- HXHX $6.29
- Technical
- Relative Strength Index (RSI)
- STTK 47.54
- HXHX N/A
- Support Level
- STTK $0.91
- HXHX N/A
- Resistance Level
- STTK $1.14
- HXHX N/A
- Average True Range (ATR)
- STTK 0.08
- HXHX 0.00
- MACD
- STTK -0.01
- HXHX 0.00
- Stochastic Oscillator
- STTK 28.35
- HXHX 0.00
About STTK Shattuck Labs Inc.
Shattuck Labs Inc is a biotechnology company specializing in the development of potential treatments for inflammatory and immune-mediated diseases. It is developing a potentially first-in-class antibody for the treatment of inflammatory bowel disease (IBD) and other inflammatory and immune-mediated diseases. The company's expertise in protein engineering and the development of novel tumor necrosis factor (TNF) receptor therapeutics comes together in its main program, SL-325, which has the potential to be a first-in-class death receptor 3 (DR3) antagonist antibody. In addition, the company is developing SL-425, a half-life extended version of SL-325, and multiple other preclinical DR3-based bispecific antibodies, for the treatment of patients with IBD.